Anti-bacterial and Anti-biofilm Evaluation of Thiazolopyrimidinone Derivatives Targeting the Histidine Kinase YycG Protein of Staphylococcus epidermidis

Zhihui Lv1†, Dan Zhao2†, Jun Chang3†, Huayong Liu1†, Xiaofei Wang1, Jinxin Zheng4, Renzheng Huang5, Zhiwei Lin1, Yongpeng Shang1, Lina Ye1, Yang Wu1*, Shiqing Han2* and Di Qu1*

1 Key Laboratory of Medical Molecular Virology of Ministry of Education and Ministry of Public Health, Institute of Medical Microbiology and Institutes of Biomedical Sciences, Shanghai Medical School of Fudan University, Shanghai, China, 2 College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing, China, 3 Department of Natural Products Chemistry, School of Pharmacy, Fudan University, Shanghai, China, 4 Department of Infectious Diseases and Shenzhen Key Lab for Endogenous Infection, Shenzhen Nanshan Hospital, Shenzhen University, Shenzhen, China, 5 Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai, China

Staphylococcus epidermidis is one of the most important opportunistic pathogens in nosocomial infections. The main pathogenicity associated with S. epidermidis involves the formation of biofilms on implanted medical devices, biofilms dramatically decrease the efficacy of conventional antibiotics and the host immune system. This emphasizes the urgent need for designing novel anti-staphylococcal biofilm agents. Based on the findings that compound 5, targeting the histidine kinase domain of S. epidermidis YycG, possessed bactericidal activity against staphylococci, 39 derivatives of compound 5 with intact thiazolopyrimidinone core structures were newly designed, 7 derivatives were further screened to explore their anti-bacterial and anti-biofilm activities. The seven derivatives strongly inhibited the growth of S. epidermidis and Staphylococcus aureus in the minimal inhibitory concentration range of 1.56–6.25 µM. All the derivatives reduced the proportion of viable cells in mature biofilms. They all displayed low cytotoxicity on mammalian cells and were not hemolytic to human erythrocytes. The biofilm inhibition activities of four derivatives (H5-32, H5-33, H5-34, and H5-35) were further investigated under shearing forces, they all led to significant decreases in the biofilm formation of S. epidermidis. These results were suggestive that the seven derivatives of compound 5 have the potential to be developed into agents for eradicating biofilm-associated infections.

Keywords: Staphylococcus epidermidis, histidine kinase YycG, minimal inhibitory concentration, minimal bactericidal concentration, anti-biofilm activity
INTRODUCTION

Staphylococcus epidermidis is one of the most important opportunistic pathogens in nosocomial infections, in particular, it is the leading cause of biofilm infections related to implanted medical devices (Otto, 2009). Once a biofilm has been established on these devices, it is difficult to eradicate because the bacteria in a biofilm are protected from attack by the host immune system and are generally much more resistant to antibiotics or biocides than their planktonic counterparts (Hoiby et al., 2011). A possible mechanism underlying this resistance is that biofilm-encased bacteria might restrict the diffusion of antibiotics due to interactions with the exopolysaccharide matrix (Lewis, 2001). Currently, the effective treatment for such biofilm infections is to remove or replace the implanted devices, resulting in substantial healthcare costs (Vuong and Otto, 2002). Biofilms are also associated with the emergence and spread of antimicrobial resistance (Römling and Balsalobre, 2012; Savage et al., 2013). In addition, with the excessive use of antibiotics in hospitals, there have been more and more reports of multi-drug resistance in staphylococci, resulting in most of the available agents having a limited efficacy in treating serious infections caused by staphylococci, such as prosthetic valve endocarditis and blood infections (Raad et al., 1998; Ventola, 2015). New strategies for combating biofilm infections, therefore, have become challenging and are attracting considerable scientific attention (Sadekuzzaman et al., 2015). In the past few decades, the development of bacterial genomics, bioinformatics, and gene manipulation have brought about new opportunities for discovering many novel protein targets for anti-bacterial agents (Moir et al., 1999; Silver, 2011).

Two-component systems (TCSs) are important regulators in most bacteria for cell adaption to environmental conditions (Stock et al., 2000; Bijlsma and Groisman, 2003). A TCS usually consists of a histidine kinase (HK) and a response regulator (Stock et al., 2000). TCSs have no human homologs or structurally similar proteins (Bem et al., 2015); thus, they have attracted increasing attention as potential anti-bacterial targets (Macielag and Goldschmidt, 2000). Among TCSs, YycG/YycF (also known as WalK/WalR) is essential in low G+C Gram-positive bacteria, such as Bacillus subtilis, Enterococcus faecalis, Staphylococcus aureus, and Streptococcus pneumoniae (Fabret and Hoch, 1998; Martin et al., 1999; Throup et al., 2000; Hancock and Perego, 2002). It has been shown that inhibitors acting directly against YycG or YycF (WalR) have bactericidal effects and are active against an array of clinically important Gram-positive pathogens (Watanabe et al., 2003; Gotoh et al., 2010; Okada et al., 2010). Using a structure-based virtual screening approach, we have found two leading compounds (compound 2 and compound 5) targeting YycG that possess not only bactericidal but also potent anti-biofilm activities against staphylococci (Qin et al., 2006; Huang et al., 2012; Liu et al., 2014).

To improve the anti-bacterial activities and reduce the toxicity to mammalian cells of leading compound 5, 39 derivatives of it were designed and synthesized by introducing different functional groups, while keeping the thiazolopyrimidine core structure intact (Zhao et al., 2014). Based on inhibitory activities against S. epidermidis, seven more-potent derivatives of compound 5 were screened out for further exploration of their bactericidal activity and anti-biofilm activity, as well as YycG phosphorylation inhibiting activity and cytotoxicity. The seven derivatives all displayed a strong bactericidal effect with low cytotoxicity on mammalian cells and were not hemolytic to human erythrocytes.

MATERIALS AND METHODS

Bacterial Strains, Culture Media, and Antibiotics

S. epidermidis ATCC 12228 (biofilm negative), S. epidermidis ATCC 35984 (biofilm positive), S. aureus ATCC 49230 and Escherichia coli ATCC 25922 were used in this study. Six clinical methicillin-resistant S. aureus (MRSA) isolates were collected from the Department of Clinical Laboratory, Shanghai General Hospital, School of Medicine, Shanghai Jiaotong University, China. Staphylococcal strains were grown in tryptic soy broth (TSB; Oxoid Ltd., Basingstoke, England), and E. coli strains were grown in Luria-Bertani broth medium. Mueller-Hinton broth (MHB; Oxoid Ltd., Basingstoke, England) was used for antimicrobial susceptibility testing. Vancomycin and ampicillin were obtained from the Sigma Chemical Co. (St Louis, MO, USA).

Synthesis of the Derivatives of Compound 5

All the 39 derivatives of compound 5 were synthesized by introducing various chemical groups, while keeping the thiazolopyrimidine core structure intact, and were provided by Nanjing University of Technology, China, and the Department of Natural Products Chemistry, School of Pharmacy, Fudan University, China. Based on the thiazolidione core structure of compound 5 [5-benzo [1,3] dioxol-5-yl-2-[5-(3-carboxy-phenyl)-furan-2-ylmethylene]-3-oxo-7-phenyl-2, 3 -dihydro-5H-thiazolo [3,2-a] pyrimidine-6-carboxylic acid ethyl ester, seven derivatives were designed and synthesized by modifying the functional groups through cyclization, aldol condensation, substitution, and hydrolyzation reactions: H5-23, 2-[5-(3-carboxy-phenyl)-furan-2-ylmethylene]-5-(4-chloro-phenyl)-3-oxo-7-phenyl-2, 3 -dihydro-5H-thiazolo [3,2-a] pyrimidine-6-carboxylic acid ethyl ester; H5-24, 3-[5-[5-(4-ethoxy-phenyl)-3-oxo-7-phenyl-5H-thiazolo[3,2-a] pyrimidin-2-ylidenemethyl]-furan-2-yl]-benzoic acid; H5-25, 3-[5-[5-(4-chloro-phenyl)-3-oxo-7-phenyl-5H-thiazolo[3,2-a] pyrimidin-2-ylidenemethyl]-furan-2-yl]-benzoic acid; H5-32: 2-[5-(3-carboxy-phenyl)-furan-2-ylmethylene]-5-(4-fluoro- phenyl)-3-oxo-7-phenyl-2,3-dihydro-5H-thiazolo[3,2-a] pyrimidine-6-carboxylic acid ethyl ester; H5-33, 3-[5-[5-(4-fluoro-phenyl)-3-oxo-7-phenyl-5H-thiazolo[3,2-a] pyrimidin-2-ylidenemethyl]-furan-2-yl]-benzoic acid; H5-34, 2-[5-(4-carboxy-phenyl)-furan-2-ylmethylene]-5-(4-chloro-phenyl)-3-
oxo-7-phenyl-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylic acid ethyl ester; H5-35, 2-[5-(4-carboxy-phenyl)furan-2-ylmethylene]-5-(4-fluorophenyl)-3-oxo-7-phenyl-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylic acid ethyl ester. The structural formulas of the derivatives are listed in Figure 1. Stock solutions of 200 mM derivatives were prepared in dimethylsulfoxide (DMSO; AMRESCO, USA) and stored at −80°C.

**Inhibition Assay for YycG’ Autophosphorylation**

The construction of the recombinant plasmid pET28a-YycG’ (containing the HATPase_c and HisKA domains of YycG) has been previously described (Liu et al., 2014). After being used to transform E. coli strain BL21(DE3), this recombinant plasmid was induced to express YycG’ protein by 0.4 mM isopropyl-1-thio-β-D-galactopyranoside at 21°C for 12 h. Then, the bacterial cells were disrupted by sonication and centrifuged, the supernatant was purified by Ni–NTA agarose (Qiagen, Los Angeles, CA, USA). The inhibitory activities of the compound 5 derivatives on the ATPase activity of the YycG’ protein were measured using the Kinase-Glo™ Luminescent Kinase Assay (Promega, Madison, WI, USA). Briefly, 2 µg purified YycG’ protein was pre-incubated with a series of dilutions of the derivatives in reaction buffer [40 mM Tris (pH 7.5), 20 mM MgCl₂ and 0.1 mg/ml BSA] at room temperature for 30 min, 4 µM ATP was added and incubated for 30 min at room temperature, then Kinase-Glo™ Reagent was added to detect the remaining amount of ATP, as reflected by luminescence intensity (RLU). In parallel, YycG’ protein with no addition of the derivatives was used as the control and ATP only was used as a blank. The rate of inhibition of protein phosphorylation (Rp) by the derivatives was calculated by the following equation:

\[
Rp = \frac{RLU(YycG’ + \text{derivative} + \text{ATP} + \text{Kinase} - \text{Glo}^\text{TM}) - RLU(YycG’ + \text{ATP} + \text{Kinase} - \text{Glo}^\text{TM})}{RLU(\text{ATP} + \text{Kinase} - \text{Glo}^\text{TM})} \times 100
\]

IC₅₀ (the concentration resulting in 50% inhibition of YycG’ protein autophosphorylation) was obtained by using Origin v7.0 software (OriginLab, Northampton, USA).

**Minimal Inhibitory Concentration (MIC) and Minimal Bactericidal Concentration (MBC) Assays of the Derivatives**

The MIC assays of the derivatives of compound 5 against S. epidermidis, S. aureus, MRSA and E. coli were performed by using the methods described previously by Wiegand et al. (2008). In brief, two-fold serial dilutions of the derivatives were

---

**FIGURE 1** | Chemical structures of seven compound 5 derivatives.
prepared in tubes containing 4 mL MHB medium, yielding final concentrations from 200 to 0.78 µM. Bacterial cultures were grown overnight and adjusted so that the bacterial suspension turbidity was equivalent to a 0.5 McFarland standard (~1 × 10^8 CFU/mL) and further diluted to 1:200 into MHB medium. The contents in the tubes were mixed thoroughly and incubated at 37°C with shaking at 220 rpm for 16–20 h. The MIC endpoint was defined as the lowest concentration at which there was no visible growth in the tubes. The MBC values were assessed by plating 100 µL samples from each negative (no visible bacterial growth) culture tube from the MIC assays onto blank MHB agar plates. After incubation at 37°C for 24 h, the bacterial colonies on the plates were counted. The MBC was the concentration at which a 99.9% reduction of the original inoculum was observed (Pridmore et al., 2011). In this assay, all the experiments were performed three times.

**Time-Killing Assays of the Derivatives against S. epidermidis**

Suspensions of S. epidermidis (1 × 10^7 CFU/mL) were prepared and separately treated with the derivatives of compound 5 or vancomycin at concentrations of 4×MIC in fresh MHB. Time-kill experiments were performed at 37°C with shaking at 220 rpm under aerobic conditions. Aliquots (1 mL) were removed from the culture medium at different time points (0, 1, 3, 5, 8, and 24 h), serially diluted and 100 µL of each of the dilutions plated out onto tryptic soy agar. After incubating at 37°C for 24 h, emergent bacterial colonies were counted, and the activity of the derivatives against fast-growing S. epidermidis cells was determined by plotting log_{10} colony counts (CFU/mL) against time. Bactericidal activity was defined as a 3-log_{10} decrease in CFU/mL. This assay was performed in triplicate and similar results were obtained.

**Anti-biofilm Activity Detection of the Derivatives**

**Microtiter Plate Assays of S. epidermidis Biofilms**

The biofilm-killing effect for immature (6 h old) biofilms was determined in TSB using a semi-quantitative assay. An overnight culture was diluted 1:200 into TSB medium with 0.25% glucose, and incubated in polystyrene 96-well plates at 37°C for 6 h. Biofilms were exposed to two-fold serial dilutions of the derivatives, and the plates were incubated for another 18 h at 37°C. Following the incubation and removal of non-adherent cells with 200 µL of phosphate-buffered saline, adherent biofilms were fixed with 95% methanol and stained with 2% (w/v) crystal violet. Then, the wells were washed three times with sterile distilled water and the plates were air dried for 2 h. The optical density of each well at 570 nm was determined using a 96-well plate spectrophotometer (DTX880, Beckman Coulter, USA).

**Determination of Cell Viability in Mature Biofilms by Confocal Laser Scanning Microscope (CLSM)**

The effect of the derivatives on cell viability in mature biofilms (24 h old) was determined using the Live/Dead Bacterial Viability method (Live/Dead BacLight, Molecular Probes, USA). Individual wells of cell-culture dishes (WPI, USA) were filled with diluted culture, after incubation at 37°C for 24 h, the planktonic cells were removed and fresh TSB containing the derivatives at concentrations of 4×MIC was added and incubated at 37°C for another 16 h. The mature biofilms were stained with SYTO 9 and propidium iodide at room temperature for 15 min, following gentle washing of the dishes with normal saline, and were observed under a Leica TCS SPS CLSM with a 63 × 1.4-NA oil-immersion objective. Further, image analysis was performed using IMARIS 7.0.0 software (Bitplane). The fluorescence quantities of biofilm were determined using ImageJ software. This assay was performed in triplicate and similar results were obtained.

**Flow-Based Biofilm Inhibition Assays by BioFlux**

The microfluidic channels of BioFlux 48-well plates (Fluxion Biosciences, South San Francisco, CA, USA) were primed with pre-warmed (37°C) TSB medium from the outlet well at a shear setting of 2 dyn/cm^2 for 10 min. Overnight bacterial culture of S. epidermidis ATCC 35984 was subcultured to mid-log phase and then diluted 1:200 in MHB medium, bacteria were seeded from the outlet well into the channel and viewing window at a shear setting of 2 dyn/cm^2 for 3 s. After 1 h incubation for bacteria attachment at 37°C, fresh TSB medium containing 2×MIC of the derivatives was flowed from the inlet well at a shear setting of 0.15 dyn/cm^2. Growth of the biofilms was monitored for up to 16 h. Images of different stages were automatically acquired at 10 min intervals with bright-field illumination.

**Cytotoxicity and Erythrocyte Hemolysis Assays**

A Cell Proliferation Kit I (MTT; Roche, Indianapolis, USA) was used to detect the cytotoxicity of the derivatives against Vero cells. Vero cells were added to 96-well microtiter plates at a concentration of 5 × 10^4 cells/well in 100 µL of culture medium. After 24 h, culture medium was replaced by 100 µL of each of the serial dilutions of the derivatives (0.78–100 µM) and the cells were incubated for 4 h in an atmosphere of 5% CO_2, then 10 µL of the MTT stock solution was added to each well and the plate returned to the 37°C incubator for 4 h. Subsequent to the incubation, the purple formazan salts were dissolved in DMSO, and the absorbance of each well was measured at wavelengths of 595 nm (test) and 655 nm (reference). Cells treated with the solvent (0.1% DMSO) were used as a blank control. The concentration of the derivatives that produced a 50% cytotoxicity effect on Vero cells (CC_{50}) was calculated using Origin v8.0 software (Origin Lab, Northampton, USA).

Hemolytic activities of the derivatives were measured on healthy human erythrocytes. A pure suspension of erythrocytes was obtained by washing a blood sample with sterile 0.9% NaCl saline solution. Erythrocytes were resuspended in normal saline to give a 5% solution, then treated with MIC, 4×MIC or 200 µM of the derivatives for 1 h at 37°C in 96-well microtiter plates. After the incubation and centrifugation at 1,000 g for 10 min, supernatants were transferred to another sterile plate and the absorbance at 570 nm was measured on a spectrophotometric microplate reader. A positive control (100% hemolysis) and a negative control (0% hemolysis) were achieved by
incubating with 1% Triton-X 100 and 0.1% DMSO, respectively. Each assay was performed in triplicate and repeated three times.

**Statistics**

Experiments were performed in triplicate and repeated at least three times. One-way analysis of variance (ANOVA) was utilized for data comparison. Differences in means were considered significant when \( P < 0.05 \).

## RESULTS

**Inhibition of the YycG' Protein Atpase Activity**

To confirm the interaction of the potential YycG inhibitors with their putative target protein, recombinant YycG' was expressed and purified (Lv et al., 2016). The enzymatic inhibitory effects of the derivatives on YycG' kinase activity were determined by using a Kinase-Glo™ Luminescent Kinase assay. The seven derivatives displayed dose-dependent inhibition of the autophosphorylation activity of YycG'. At the concentration 100 \( \mu \text{M} \), H5-23, H5-24, H5-25, H5-32, H5-33, H5-34, and H5-35 inhibited the enzymatic activity of 2 \( \mu \text{g YycG'} \) protein in the presence of 4 \( \mu \text{M ATP} \) by 64.78, 49.92, 51.42, 55.61, 77.04, 80.72, and 63.94%, respectively. The IC\(_{50}\) values of the seven derivatives were 77.18, 82.16, 80.23, 83.91, 64.90, 61.94, and 78.19 \( \mu \text{M} \), respectively (Table 1).

**Antimicrobial Activity of the Derivatives against Planktonic Bacteria**

We determined the MIC values of the derivatives by using a standard tube-dilution assay. The seven derivatives (H5-23, H5-24, H5-25, H5-32, H5-33, H5-34, and H5-35) inhibited bacterial growth of S. epidermidis ATCC 35984, and the MIC values were 1.56, 1.56, 1.56, 3.13, 3.13, 3.13, and 3.13 \( \mu \text{M} \), respectively. Furthermore, they showed similar anti-bacterial activities against S. epidermidis ATCC 12228 and S. aureus ATCC 49230, whereas none of them showed anti-bacterial activity on E. coli strain ATCC 25922, even at the concentration of 200 \( \mu \text{M} \) (Table 2). Subsequently, the bactericidal activities of these derivatives against planktonic S. epidermidis ATCC 35984 cells were investigated. All seven derivatives showed bactericidal activities, and the MBC values were 25, 50, 50, 12.5, 25, and 12.5 \( \mu \text{M} \) (4× to 32× MIC), respectively (Table 1).

### TABLE 1 | Biological activities of seven derivatives of compound 5.

| Derivativesa | Molecular Formula | MW (g/mol) | MICb (\( \mu \text{M} \)) | MBCb (\( \mu \text{M} \)) | MBKCb (\( \mu \text{M} \)) | IC\(_{50}\)b (\( \mu \text{M} \)) | CMCC (\( \mu \text{M} \)) | Hemolysisc (%), 3% PBSc |
|--------------|------------------|------------|-----------------|-----------------|-----------------|-----------------|-----------------|------------------|
| Compound 5   | C\(_{32}\)H\(_{43}\)N\(_{2}\)O\(_{8}\)S | 620        | 6.25            | 25              | 50              | N/D             | >200            | 0.31 ± 0.16      | 0.51 ± 0.06      |
| H5-23        | C\(_{30}\)H\(_{42}\)Cl\(_{2}\)O\(_{6}\)S | 610        | 1.56            | 25              | 100             | 77.18           | >200            | 0.27 ± 0.35      | 0.27 ± 0.01      |
| H5-24        | C\(_{30}\)H\(_{42}\)Na\(_{2}\)O\(_{6}\)S | 534        | 1.56            | 50              | 50              | 82.16           | >200            | 0.17 ± 0.11      | 0.32 ± 0.05      |
| H5-25        | C\(_{30}\)H\(_{42}\)O\(_{6}\)S | 538        | 1.56            | 50              | 100             | 80.23           | >200            | 0.27 ± 0.01      | 0.39 ± 0.09      |
| H5-32        | C\(_{32}\)H\(_{43}\)Cl\(_{2}\)O\(_{6}\)S | 594        | 3.13            | 100             | 25              | 83.91           | >200            | 0.15 ± 0.05      | 0.24 ± 0.05      |
| H5-33        | C\(_{32}\)H\(_{43}\)Cl\(_{2}\)O\(_{7}\)S | 522        | 3.13            | 12.5            | 12.5            | 64.90           | >200            | 0.15 ± 0.06      | 0.32 ± 0.05      |
| H5-34        | C\(_{30}\)H\(_{42}\)Cl\(_{2}\)O\(_{6}\)S | 610        | 3.13            | 25              | 25              | 61.94           | >200            | 0.22 ± 0.57      | 0.19 ± 0.01      |
| H5-35        | C\(_{32}\)H\(_{43}\)Cl\(_{2}\)O\(_{6}\)S | 594        | 3.13            | 12.5            | 25              | 78.19           | >200            | 0.17 ± 0.05      | 0.27 ± 0.10      |

MW, molecular weight; N/D, not determined.
aStock solutions (200 \( \mu \text{M} \)) of the derivatives were prepared in DMSO.
bMIC, MBC, and MBKC represent the minimal inhibitory concentration, minimal bactericidal concentration and minimal biofilm-killing concentration of the derivatives against S. epidermidis ATCC 35984.
cIC\(_{50}\) represents half maximal inhibitory concentration of the derivatives, which inhibit half of the autophosphorylation of recombinant YycG' determined by the Kinase-Glo™ Luminescent Kinase Assay kit.
dCMCC represents the derivative concentration that produces 50% cytotoxicity effects on Vero cells. The highest concentration tested in the experiment was 200 \( \mu \text{M} \).
eHemolytic activities of the derivatives were determined on healthy human erythrocytes at their MICs and 200 \( \mu \text{M} \) against S. epidermidis ATCC 35984.

## Activities of the Derivatives against Fast-Growing S. epidermidis

We used a time-kill assay to determine the effectiveness of the derivatives against fast-growing S. epidermidis cells. Four
derivatives (H5-32, H5-33, H5-34, and H5-35) as well as vancomycin at the concentration of 4×MIC were separately added into fresh MHB cultures. The starting bacterial inoculum was ~1×10^7 CFU/mL. Untreated control bacterial cells grew fast (increasing >3 log_{10} CFU/mL over a 24 h period). All of the derivatives exhibited bactericidal activity in growing cultures of S. epidermidis with a 3-log reduction in CFU/mL within 1 h, whilst vancomycin only caused a decrease of ~1 log after 1 h (P < 0.001), and exhibited a more protracted bactericidal activity than the four derivatives as >5 h were required to achieve a bactericidal effect (Figure 2).

**Activities of the Derivatives against Young Biofilms**

Effects of the derivatives on young biofilms of S. epidermidis ATCC 35984 were determined in 96-well polystyrene microtiter plates. After inoculation, the bacteria in the wells of the plates were incubated for 6 h to form immature (young) biofilms, and then two-fold serial dilutions of the derivatives were added and incubated for another 18 h. Young biofilm treated with 0.1% DMSO served as a negative control. The minimal biofilm-killing concentration ranged from 12.5 to 100 µM. The derivatives H5-32, H5-33, H5-34, and H5-35 showed stronger biofilm-killing effects at the concentrations of 12.5 or 25 µM than other derivatives (Table 1); therefore, these four derivatives were further investigated for inhibition of biofilm formation activities with a BioFlux 1,000.

After pumping bacteria into the channel of the BioFlux 1,000 and incubating for 1 h, fresh TSB medium containing 2×MIC of the derivatives was separately flowed from the inlet well at a shear setting of 0.15 dyn/cm^2, and then biofilm formation was monitored for another 16 h. In the channels treated with the derivatives of compound 5 (H5-32, H5-33, H5-34, and H5-35) there was a significant decrease in the biofilm formation of S. epidermidis 35984. When grown in the absence of the inhibitors, bacteria showed initial attachment (1 h), microcolony formation (3 h), biofilm development (8 h), and firmly attached to the microfluidic flow channel and formed a robust biofilm (16 h) (Figure 3; also see the kinetic movies of biofilm formation, Supplementary Videos 1–5 in the supplemental material).

**Activity of the Derivatives against Mature Biofilms**

The effects of the derivatives on cell viability in mature biofilms of S. epidermidis were detected by a CLSM with Live/Dead staining. The inoculated bacteria in the wells of plates were incubated for 24 h to form mature biofilms. All of the derivatives reduced the proportion of viable cells in mature biofilms in varying degrees, especially H5-23, H5-24, H5-33, and H5-35 (85.7, 77.5, 88.4, and 71.7%, respectively), as shown in Figure 4. As has been previously described (Liu et al., 2014), vancomycin (128 µg/mL) showed little effect on the bacterial viability in the biofilms, reduced living cells in mature biofilm only by 11.4%.
Cytotoxicity and Hemolysis of the Derivatives \textit{In vitro}

The cytotoxicity of the derivatives against Vero cells (African green monkey kidney epithelial cells) was assessed by using the MTT assay. Cells treated with 0.1% DMSO were used as a negative control. Compared with the control group, no obvious cytotoxic effects of the derivatives against Vero cells were detected, the CC\textsubscript{50} values of the tested derivatives were all higher than the highest concentration used in this study (200 \textmu M; Table 1).

All the seven derivatives displayed no obvious hemolysis on healthy human erythrocytes at MICs and even up to the concentration of 200 \textmu M (Table 1). As a positive control, treatment with 1% Triton-X100 resulted in 100% hemolysis of human erythrocytes, while no hemolysis was observed in cells that were treated with 0.1% DMSO, as a negative control.
**DISCUSSION**

*S. epidermidis* is the main cause of biomaterial-associated infections. The most important virulence factors associated with *S. epidermidis* are related to biofilm formation, whereas *S. aureus* produces toxins and tissue-damaging exoenzymes (Vuong and Otto, 2002). Biofilms on the inert surfaces of implanted medical devices impair the penetration of antibiotics and impede the host immune response, ultimately requiring surgical removal of the infected biomaterial and subsequent replacement (Otto, 2009; Hoiby et al., 2011). In this regard, effective chemical agents for inhibition and eradication of biofilms are urgently needed. With a structure-based virtual screening approach, we found two leading compounds (compound 2 and compound 5) targeting YycG that not only were bactericidal, but also possessed potent biofilm-killing activity against *S. epidermidis* (Qin et al., 2006; Huang et al., 2012; Liu et al., 2014). Compound 2 had a thiazolidione core structure, while compound 5 had a thiazolopyrimidine core. A series of derivatives of compound 2 have been synthesized and evaluated for their anti-bacterial and anti-biofilm activities in our previous work (Huang et al., 2012; Liu et al., 2014). In the present study, we designed and synthesized a series of derivatives of compound 5 by introducing different functional groups, while keeping the thiazolopyrimidine core structure intact, to improve the anti-bacterial and anti-biofilm activities (Zhao et al., 2014).

The YycG/YycF (also known as WalK/WalR) TCS was first recognized in *B. subtilis* by Fabret and Fukuchi et al. and appears to be essential (Fabret and Hoch, 1998; Fukuchi et al., 2000). It is highly conserved and specific to low G+C Gram-positive bacteria, such as *B. subtilis, Streptococcus pneumoniae, S. aureus, S. epidermidis* and *Listeria monocytogenes* (Fabret and Hoch, 1998; Martin et al., 1999; Throup et al., 2000; Kallipolitis and Ingmer, 2001; Qin et al., 2006). YycG/YycF plays major roles in regulating cell-wall metabolism (Biscia et al., 2007; Dubrac et al., 2008), cell viability and division (Fukuchi et al., 2000; Biscia et al., 2007), virulence-factor expression (Ng et al., 2005; Senadheera et al., 2005), lipid integrity (Mokedano et al., 2005; Ng et al., 2005), exopolysaccharide biosynthesis and biofilm formation (Senadheera et al., 2005; Shemesh et al., 2006; Ahn and Burne, 2007). Because of its essential biological functions, the YycG/F TCS has been considered as an attractive target for anti-infective therapeutics. It has been reported that inhibitors targeting WalK (YycG), alkylmycin B and aranosinosin B, had anti-bacterial activity against *S. aureus* and *B. subtilis* in the low MIC range (Watanabe et al., 2003; Okada et al., 2010). Based on virtual screening, inhibitors targeting VicK (YycG) that actively inhibited the growth of *Streptococcus pneumoniae* were discovered by Li et al. (2009). Here, we mainly focused on studying the anti-biofilm properties of the newly synthesized compound 5 derivatives. By substituting different functional groups, while keeping the core structure intact, 39 derivatives of compound 5 were synthesized (Zhao et al., 2014). By testing the anti-staphylococcal activities of the derivatives, seven of them (H5-23, H5-24, H5-25, H5-32, H5-33, H5-34, and H5-35) were shown to have more potent anti-bacterial and anti-biofilm activities than leading compound 5. Additionally, four derivatives (H5-32, H5-33, H5-34, and H5-35) exhibited antimicrobial activities against six MRSA clinical isolates (MICs from 3.13 to 6.25 M), and produced a ≥99.9% reduction in the bacterial cell count at concentrations of 8- to 32-fold higher than their MICs (see Supplementary Table 1 in the supplemental material). We also determined the antimicrobial activities of the four derivatives (H5-32, H5-33, H5-34, and H5-35) against *Enterococcus faecalis* OG1RF (from the American Type Culture Collection) by using a standard tube-dilution assay. The four derivatives displayed anti-bacterial activities on *Enterococcus faecalis* OG1RF. This was suggestive that the derivatives may be applied to infection by *Enterococcus faecalis*, although this needs further testing with more clinical strains. In the derivatives containing a substituent on the phenyl ring, such as H5-23 (MIC = 1.56 M) and H5-25 (MIC = 1.56 M) with a 4-Cl substituent, H5-24 with a 4-methoxy substituent (MIC = 1.56 M) presented a much more potent anti-bacterial activity than the leading compound 5. H5-25 and H5-33, without the ester moiety on the 6 position of the core ring, showed the same anti-bacterial activity as H5-23 and H5-32, which revealed that the removal of the ester did not decrease the anti-bacterial activity. Moreover, the substitution site of the carboxyl group on the side chain may decrease the anti-bacterial activity (H5-23 vs. H5-34). Furthermore, compared with the MBCs of H5-32 and H5-33, removing the ester increased the bactericidal activity by eight times.

Bacteria within a biofilm can be 100–1,000 times more resistant to antibiotics than corresponding planktonic cells (Imaizumi et al., 2003). All the seven derivatives exhibited bactericidal activities against *S. epidermidis* cells in mature biofilms, especially the four derivatives H5-23, H5-24, H5-33, and H5-35, which significantly decreased cell viability in mature biofilms to 85.7, 77.5, 88.4, and 71.7%, respectively, at concentrations of 4×MIC; compared to 128 μg/ml of vancomycin treatment, which only reduced *S. epidermidis* living cells in the mature biofilm by 11.4% (Liu et al., 2014). We chose one strong biofilm-forming strain of MRSA (strain 226) and tested the anti-biofilm activities of the four derivatives (H5-32, H5-33, H5-34, and H5-35) by microtiter plate assay. All derivatives showed biofilm-killing effects on 6 h young biofilms of *S. aureus*, and the minimal biofilm-killing concentration was 200 μM. The anti-biofilm activities of these YycG HK inhibitors need to be tested against more *S. aureus* strains in future studies. The seven derivatives inhibited autophosphorylation of YycG, with IC50 values ranging from 61.94 to 83.91 μM. This was suggestive that the derivatives may elicit their anti-bacterial and anti-biofilm effect through inhibiting the enzyme activity of the HK domain of YycG, which is an important TCS that positively regulates biofilm formation. To clarify whether the YycG inhibitors target other HKs, we cloned and expressed HisKA and HATPase_c domains of *S. epidermidis* ArlS (designated as ArlS), which are similar to those of YycG (as shown in Supplementary Figure 1). The effects of the four derivatives (H5-32, H5-33, H5-34, and H5-35) on the autophosphorylation of ArlS were determined by using a Kinase-Glo™ Luminescent Kinase Assay. None of them showed an inhibitory effect on the autophosphorylation of ArlS, even at the highest concentration (200 μM; see Supplementary Table 2 in the supplemental material). This was suggestive that
the derivatives had a certain degree of specificity dependent on the characteristics of the HATPase_c domain structure of the different HKs. In addition, the derivatives showed low toxicity to mammalian cells and healthy human erythrocytes at the highest concentration (200 µM).

*S. epidermidis* is an opportunist pathogen causing infections of implanted medical devices, primarily due to its ability to colonize and form biofilms on inert surfaces, which subsequently act as a nidus for systemic dissemination (Wang et al., 2011). The fluid dynamics of blood flow exert substantial shear forces around the indwelling devices and influence biofilm formation (Lam et al., 2014). To simulate the fluid dynamics of the *in vivo* milieu, a flow-based live cell imaging system, BioFlux 1,000, was used for developing biofilms. Four derivatives (H5-32, H5-33, H5-34, and H5-35) were selected and incubated with bacteria at a shear setting of 0.15 dyn/cm² for 16 h. All of them strongly inhibited biofilm formation under conditions of shear forces, which was suggestive that the derivatives of compound 5 were suitable candidates for the prevention of biofilm formation on implanted medical devices.

In the present study, the seven newly designed derivatives with intact thiazolopyrimidine core structures, displayed higher anti-bacterial and anti-biofilm activities than that of leading compound 5. However, two derivatives, H5-34 and H5-35, showed limited aqueous solubility characteristics at the highest concentration (200 µM) and precipitated after incubation at 37°C for 12 h, which may hinder these derivatives as drug candidates for subsequent clinical steps. The derivatives will need further modifying to improve the thiazole compounds' drug-like properties (including higher aqueous solubility and permeability, and lower toxicity), increasing their strong anti-biofilm properties for eradicating biofilm-associated infections and multidrug-resistant bacterial infections.

**REFERENCES**

Ahn, S. J., and Burne, R. A. (2007). Effects of oxygen on biofilm formation and the AtIA autolysin of *Streptococcus mutans*. *J. Bacteriol.* 189, 6293–6302. doi: 10.1128/JB.00546-07

Bem, A. E., Velikova, N., Pellicer, M. T., Baarlen, P., Marina, A., and Wells, J. M. (2015). Bacterial histidine kinases as novel antibacterial drug targets. *ACS Chem. Biol.* 10, 213–224. doi: 10.1021/cb5007135

Bijsma, J. J. E., and Groisman, E. A. (2003). Making informed decisions: regulatory interactions between two-component systems. *Trends Microbiol.* 11, 359–366. doi: 10.1016/S0966-842X(03)00176-8

Bisicchia, P., Noone, D., Lioliou, E., Howell, A., Quigley, S., Jensen, T., et al. (2007). The essential YycG two-component system controls cell wall metabolism in *Bacillus subtilis*. *Mol. Microbiol.* 65, 180–200. doi: 10.1111/j.1365-2958.2007.05782.x

Dubrac, S., Bisicchia, P., Devine, K. M., and Msadek, T. (2008). A matter of life and death: cell wall homeostasis and the WallR (YycG) essential signal transduction pathway. *Mol. Microbiol.* 70, 1307–1322. doi: 10.1111/j.1365-2958.2008.06483.x

Fabret, C., and Hoch, J. A. (1998). A two-component signal transduction system essential for growth of *Bacillus subtilis* implicates anti-infective therapy. *J. Bacteriol.* 180, 6375–6383.

Fukuchi, K., Kasahara, Y., Asai, K., Kobayashi, K., Moriya, S., and Ogasawara, N. (2000). The essential two-component regulatory system encoded by yycF and yycG modulates expression of the ftsAZ operon in *Bacillus subtilis*. *Microbiology* 146, 1573–1583. doi: 10.1099/00221287-146-7-1573

Gotoh, Y., Doi, A., Furuta, E., Dubrac, S., Ishizaki, Y., Okada, M., et al. (2010). Novel antibacterial compounds specifically targeting the essential WallR response regulator. *J. Antibiot.* 63, 127–134. doi: 10.1038/ja.2010.4

Hancock, L., and Perego, M. (2002). Two-component signal transduction in *Enterococcus faecalis*. *J. Bacteriol.* 184, 5819–5825. doi: 10.1128/JB.184.21.5819-5825.2002

Holby, N., Ciofu, O., Johansen, H. K., Song, Z. J., Moser, C., Jensen, P. Ø., et al. (2011). The clinical impact of bacterial biofilms. *Int. J. Oral Sci.* 3, 55–65. doi: 10.4248/IJOS11026

Huang, R. Z., Zheng, L. K., Liu, H. Y., Pan, B., Hu, J., Zhu, T., et al. (2012). Thiazolidinedione derivatives targeting the histidine kinase YycG are effective against both planktonic and biofilm-associated *Staphylococcus epidermidis*. *Acta Pharmacol. Sin.* 33, 418–425. doi: 10.1038/aps.2011.166

Imaizumi, T., Tran, H. G., Swartz, T. E., Briggs, W. R., and Kay, S. A. (2003). FKF1 is essential for photoperiodic-specific light signalling in Arabidopsis. *Nature* 426, 302–306. doi: 10.1038/nature02900

Kallipolitis, B. H., and Ingmer, H. (2001). *Listeria monocytogenes* response regulators important for stress tolerance and pathogenesis. *FEMS Microbiol. Lett.* 204, 111–115. doi: 10.1111/j.1574-6968.2001.tb0872.x

Lam, H., Kesselley, A., Stegalkina, S., Kleanthous, H., and Yethon, J. A. (2014). Antibodies to PhnD inhibit staphylococcal biofilms. * Infect. Immun.* 82, 3764–3774. doi: 10.1128/IAI.02168-14

**AUTHOR CONTRIBUTIONS**

DQ, SH, and YW designed the research; ZL, DZ, JC, and HL participated in most of the experiments; ZL, XW, JZ, RH, ZL, YS, LY analyzed the data; ZL drafted the manuscript; DQ, SH, and JC revised the manuscript.

**FUNDING**

This work was supported by the National Natural Science Foundation of China (81271791, 81571955, 81573268, 81671982), the National High-Tech and Development Plan of China (2014AA021404), the National Science and Technology Major Project of China (2012ZX10002002), Six Talent Peaks Project in Jiangsu Province (No: 2015-SWYY-016) and the Shanghai Municipal Committee of Science and Technology (14431900300, 15431900400) and the Shanghai Municipal Committee of Science and Technology (14431900300, 15431900400).

**ACKNOWLEDGMENTS**

The six MASR clinical strains used in this study were kindly provided by Professor Qingzhong Liu from the Department of Clinical Laboratory, Shanghai General Hospital, School of Medicine, Shanghai Jiaotong University, China.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: http://journal.frontiersin.org/article/10.3389/fmicb.2017.00549/full#supplementary-material
Lewis, K. (2001). Riddle of biofilm resistance. Antimicrob. Agents Chemother. 45, 999–1007. doi: 10.1128/AAC.45.4.999-1007.2001

Li, N., Wang, F., Niu, S., Cao, J., Wu, K., Li, Y., et al. (2009). Discovery of novel inhibitors of Streptococcus pneumoniae based on the virtual screening with the homology-modelled structure of histidine kinase (VicK). BMC Microbiol. 9:129. doi: 10.1186/1471-2180-9-129

Liu et al. Antimicrobial Activities of YycG Inhibitors

Macielag, M. J., and Goldschmidt, R. (2000). Inhibitors of bacterial two-component signalling systems. Expert Opin. Invest. Drugs 9, 2351–2369. doi: 10.1517/13543784.9.10.2351

Martin, P. K., Li, T., Sun, D., Biek, D. P., and Schmid, M. B. (1999). Role in cell permeability of an essential two-component system in Staphylococcus aureus. J. Bacteriol. 181, 3666–3673.

Mohedano, M. L., Overweg, K., De La Fuente, A., Reuter, M., Albere, S., Mulholland, F., et al. (2005). Evidence that the essential response regulator YycF genes and alters membrane composition. J. Bacteriol. 187, 2357–2367. doi: 10.1128/JB.187.7.1379-1385.2005

Moreira, D. T., Shaw, K. J., Hare, R. S., and Vovis, G. F. (1999). Genomics and antimicrobial drug discovery. Antimicrob. Agents Chemother. 43, 439–446.

Ng, W. L., Tsui, H. C., and Winkler, M. E. (2005). Regulation of the psbA virulence factor and essential pscB murein biosynthetic genes by the phosphorylated VicR (YycF) response regulator in Streptococcus pneumoniae. J. Bacteriol. 187, 7444–7459. doi: 10.1128/JB.187.12.7444-7459.2005

Okada, A., Igarashi, M., Okajima, T., Kinoshita, N., Umemiya, M., Sawa, R., et al. (2010). Walkycin B targets WalK (YycG), a histidine kinase essential for bacterial cell growth. J. Antibiot. 63, 89–94. doi: 10.1038/ja.2009.128

Otto, M. (2009). Staphylococcus epidermidis—the ‘accidental’ pathogen. Nat. Rev. Microbiol. 7, 555–567. doi: 10.1038/nrmicro2182

Pridmore, A., Burch, D., and Lees, P. (2011). Determination of minimum inhibitory and minimum bactericidal concentrations of tiamulin against field isolates of Actinobacillus pleuropneumoniae. Vet. Microbiol. 151, 409–412. doi: 10.1016/j.vetmic.2011.03.016

Qin, Z., Zhang, J., Xu, B., Chen, L., Wu, Y., Yang, X., et al. (2006). Structure-based discovery of inhibitors of the YycG histidine kinase: new chemical leads to combat Staphylococcus epidermidis infections. BMC Microbiol. 6:96. doi: 10.1186/1471-2180-6-96

Raad, I., Alrahwan, A., and Rolston, K. (1998). Staphylococcus epidermidis: emerging resistance and need for alternative agents. Clin. Infect. Dis. 26, 1182–1187. doi: 10.1086/520285

Römling, U., and Balsalobre, C. (2012). Biofilm infections, their resilience to therapy and innovative treatment strategies. J. Intern. Med. 272, 541–561. doi: 10.1111/j.1365-2923.2012.02872.x

Sadekuzzaman, M., Yang, S., Mizan, M. F. R., and Ha, S. D. (2015). Current and recent advanced strategies for combating biofilms. Comp. Rev. Food Sci. Food Saf. 14, 491–509. doi: 10.1111/1541-4337.12144

Savage, V. J., Chopra, I., and O’Neill, A. J. (2013). Staphylococcus aureus biofilms promote horizontal transfer of antibiotic resistance. Antimicrob. Agents Chemother. 57, 1968–1970. doi: 10.1128/AAC.02008-12

Senadheera, M. D., Guggenheim, B., Spatafora, G. A., Huang, Y. C., Choi, J., Hung, D. C., et al. (2005). A VicRK signal transduction system in Streptococcus mutans affects gtfBCD, gbpB, and vicR expression, biofilm formation, and genetic competence development. J. Bacteriol. 187, 4064–4076. doi: 10.1128/JB.187.12.4064-4076.2005

Shemesh, M., Tam, A., Feldman, M., and Steinberg, D. (2006). Differential expression profiles of Streptococcus mutans vicR, gtf and vicR genes in the presence of dietary carbohydrates at early and late exponential growth phases. Carbohydr. Res. 341, 2090–2097. doi: 10.1016/j.carres.2006.05.010

Silver, L. L. (2011). Challenges of antibacterial discovery. Clin. Microbiol. Rev. 24, 71–109. doi: 10.1128/CMR.00030-10

Stock, A. M., Robinson, V. L., and Goudreau, P. N. (2000). Two-component signal transduction. Annu. Rev. Biochem. 69, 183–215. doi: 10.1146/annurev.biochem.69.1.183

Throup, J. P., Koreskje, K. B., Bryant, A. P., Ingraham, K. A., Chalker, A. F., Ge, Y., et al. (2000). A genomic analysis of two-component signal transduction in Streptococcus pneumoniae. Mol. Microbiol. 35, 566–576. doi: 10.1046/j.1365-2958.2000.01725.x

Ventola, C. L. (2015). The antibiotic resistance crisis part I: causes and threats. Pharm. Ther. 40:277.

Vuong, C., and Otto, M. (2002). Staphylococcus epidermidis infections. Microbes Infect. 4, 481–489. doi: 10.1053/S1286-4579(02)01563-0

Wang, R., Khan, B. A., Cheung, G. Y., Bach, T.-H. L., Jameson-Lee, M., Kong, K.-F., et al. (2011). Staphylococcus epidermidis surfactant peptides promote biofilm maturation and dissemination of biofilm-associated infection in mice. J. Clin. Invest. 121, 238–248. doi: 10.1172/JCI42520

Watanabe, T., Hashimoto, Y., Yamamoto, K., Hirao, K., Ishihama, A., Hino, M., et al. (2003). Isolation and characterization of inhibitors of the essential histidine kinase, YycG in Bacillus subtilis and Staphylococcus aureus. J. Antibiot. 56, 1045–1052. doi: 10.7164/antibiotics.56.1045

Wiegand, I., Hilpert, K., and Hancock, R. E. (2008). Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat. Protoc. 3, 163–175. doi: 10.1038/nprot.2007.521

Zhao, D., Chen, C., Liu, H., Zheng, L., Tong, Y., Qu, D., et al. (2014). Biological evaluation of halogenated thiazolo[3,2-a]pyrimidin-3-one carboxylic acid derivatives targeting the YycG histidine kinase. Eur. J. Med. Chem. 87, 500–507. doi: 10.1016/j.ejmech.2014.09.096

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Lv, Zhao, Chang, Liu, Wang, Zheng, Huang, Lin, Shang, Ye, Wu, Han and Qu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.